camptothecin has been researched along with Osteosarcoma in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (9.38) | 18.2507 |
| 2000's | 20 (62.50) | 29.6817 |
| 2010's | 8 (25.00) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, HB; Fan, Z; Fong, HH; Pezzuto, JM; Sun, H; Tan, GT; Zhang, H | 1 |
| Bao, M; Wang, W; Zhang, F; Zhao, X | 1 |
| Gordon, N; Hollomon, MG; Kleinerman, ES; Santiago-O'Farrill, JM | 1 |
| Berland, E; Filipski, E; Guettier, C; Lévi, F; Okyar, A; Ozturk, N; van der Horst, GT | 1 |
| Korde, A; Kumar, C; Lohar, SP; Samuel, G; Vats, K | 1 |
| Mukai, S; Naito, Y; Nojima, H; Ohno, S; Yabuta, N | 1 |
| Chen, X; Kent, MS; Rodriguez, CO; Zhang, J | 1 |
| Emond, MJ; Lauper, JM; Mao, FJ; Monnat, RJ; Sidorova, JM | 1 |
| Adachi, S; Hiraumi, Y; Itoh, K; Matsubara, H; Naka, N; Nakahata, T; Sano, K; Watanabe, K; Watanabe, M; Yoshioka, K; Yui, Y | 1 |
| Hou, W; Li, J; Liao, J; Liu, J; Liu, X; Stark, JM; Wang, J; Wang, P; Xie, Y; Xu, X; Yao, L; Zhong, J; Zhu, B | 1 |
| Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K | 1 |
| Arizono, Y; Hamada, Y; Naganuma, H; Nakajima, Y; Tasaka, K; Yoshikawa, H | 1 |
| Boven, E; Bras, J; Gerritsen, WR; Haisma, HJ; Kruyt, FA; Molenaar, B; Oosterhoff, D; Pinedo, HM; Schaap, GR; van Beusechem, VW; Witlox, MA; Wuisman, PI | 1 |
| Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P | 1 |
| Cheshire, PJ; Daw, N; Germain, GS; Gilbertson, R; Harwood, FC; Houghton, PJ; Jenkins, JJ; Leggas, M; Panetta, JC; Peterson, J; Schuetz, JD; Stewart, CF | 1 |
| Crews, KR; Daw, NC; Liu, T; Rodriguez-Galindo, C; Santana, VM; Stewart, CF | 1 |
| Agner, J; Bartek, J; Falck, J; Lukas, J | 1 |
| Hata, A; Kageyama, H; Koseki, H; Lin, L; Nakagawara, A; Nakamura, Y; Ozaki, T; Simonds, WF; Takada, Y; Zhang, JH | 1 |
| Cho, CH; Chung, JH; Kim, BU; Lee, CH; Lee, SY; Yoo, E | 1 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Gonos, ES; Lourda, M; Trougakos, IP | 1 |
| Crassard, N; Frappaz, D; Marec-Bérard, P; Philip, T; Ranchin, B; Schell, M; Thiesse, P | 1 |
| Chen, X; Jayaraman, L; Ko, LJ; Prives, C | 1 |
| Agrawal, S; Chen, J; Chen, L; Le, LP; Oliver, P; Wang, H; Zeng, X; Zhang, R; Zhou, W | 1 |
| Gilbert, B; Giovanella, BC; Kleinerman, E; Knight, V; Koshkina, N; Waldrep, C | 1 |
| Gilbert, BE; Jia, SF; Kleinerman, ES; Knight, V; Koshkina, NV; Waidrep, C; Worth, LL | 1 |
| Gilbert, BE; Giovanella, BC; Kleinerman, ES; Knight, V; Koshkina, NV; Waldrep, JC | 1 |
| Binderup, L; Hansen, CM; Hansen, D; Holm, PK | 1 |
| Bissery, MC; D'Attino, RM; Filipski, E; Garufi, C; Granda, TG; Lévi, F; Terzoli, E; Vrignaud, P | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
| Albor, A; El-Hizawi, S; Kulesz-Martin, M; Lagowski, JP | 1 |
| Cheshire, PJ; Houghton, JA; Houghton, PJ; Myers, L; Stewart, CF; Synold, TW | 1 |
2 review(s) available for camptothecin and Osteosarcoma
| Article | Year |
|---|---|
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
1 trial(s) available for camptothecin and Osteosarcoma
| Article | Year |
|---|---|
Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Drug Interactions; Female; Humans; Ifosfamide; Irinotecan; Male; Osteosarcoma; Pharmacokinetics | 2004 |
29 other study(ies) available for camptothecin and Osteosarcoma
| Article | Year |
|---|---|
Pseudoirroratin A, a new cytotoxic ent-kaurene diterpene from Isodon pseudo-irrorata.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Diterpenes; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Female; Humans; Inhibitory Concentration 50; KB Cells; Lamiaceae; Lung Neoplasms; Male; Molecular Conformation; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Osteosarcoma; Ovarian Neoplasms; Plants, Medicinal; Prostatic Neoplasms; Spectrophotometry, Ultraviolet; Stereoisomerism; Tumor Cells, Cultured | 2002 |
Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.
Topics: Camptothecin; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; DEAD-box RNA Helicases; DNA Damage; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Osteosarcoma; Proteasome Endopeptidase Complex; Protein Binding; Proteolysis; RNA-Binding Proteins; RNA, Messenger | 2020 |
Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Autophagy; Autophagy-Related Protein 5; Bone Neoplasms; Buthionine Sulfoximine; Camptothecin; Caspases; Cell Line, Tumor; Cell Survival; Enzyme Activation; Gene Knockdown Techniques; Membrane Potential, Mitochondrial; Mice; Microtubule-Associated Proteins; Osteosarcoma; Oxidative Stress | 2013 |
Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Weight; Camptothecin; Cell Line, Tumor; Chronotherapy; Circadian Rhythm; Cyclosporins; Endpoint Determination; Female; Ileum; Irinotecan; Mice; Mucous Membrane; Osteosarcoma; RNA, Messenger; Time Factors | 2014 |
Camptothecin Enhances Cell Death Induced by (177)Lu-EDTMP in Osteosarcoma Cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Camptothecin; Cell Death; Cell Line, Tumor; Cell Proliferation; CHO Cells; Combined Modality Therapy; Cricetulus; Drug Synergism; Humans; Lutetium; Organometallic Compounds; Organophosphorus Compounds; Osteosarcoma; Radioisotopes; Radiopharmaceuticals | 2014 |
ELAS1-mediated inhibition of the cyclin G1-B'γ interaction promotes cancer cell apoptosis via stabilization and activation of p53.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Camptothecin; Cell Line, Tumor; Chemoradiotherapy; Cyclin G1; Doxycycline; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Osteosarcoma; Peptides; Phosphorylation; Protein Binding; Protein Phosphatase 2; Tumor Suppressor Protein p53 | 2015 |
Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bone Neoplasms; Camptothecin; Cell Line; Cell Line, Tumor; Conserved Sequence; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Dogs; Doxorubicin; Humans; Kidney; Melanoma; Mice; Models, Animal; Molecular Sequence Data; Osteosarcoma; Sequence Alignment; Sequence Homology, Amino Acid; Tumor Suppressor Protein p53 | 2009 |
The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage.
Topics: Antineoplastic Agents; Bone Neoplasms; Bromodeoxyuridine; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Cisplatin; DNA Damage; Exodeoxyribonucleases; Fibroblasts; Fluorouracil; Histones; Humans; Hydroxyurea; Osteosarcoma; RecQ Helicases; Werner Syndrome Helicase | 2010 |
Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8.
Topics: Animals; Camptothecin; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Irinotecan; Lung Neoplasms; Mesoderm; Mice; Mice, Inbred C3H; Osteosarcoma; Signal Transduction | 2010 |
Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; DNA Breaks, Double-Stranded; DNA Repair; Enzyme Activation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HeLa Cells; Histones; Humans; Neoplasms; Osteosarcoma; Phosphoprotein Phosphatases; Phosphorylation; RNA, Small Interfering; Substrate Specificity | 2011 |
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Cell Survival; Cisplatin; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Fibrosarcoma; Flow Cytometry; Glioma; Humans; Membrane Glycoproteins; Osteosarcoma; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Mice; Mice, Nude; Osteosarcoma; Prodrugs; Transduction, Genetic; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan | 2004 |
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Proteins; Osteosarcoma; Quinazolines; Xenograft Model Antitumor Assays | 2004 |
Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; cdc25 Phosphatases; Cell Cycle; Cell Line, Transformed; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cisplatin; Cyclin E; DNA; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Flow Cytometry; Humans; Kinetics; Osteosarcoma; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; Radiation, Ionizing; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Ultraviolet Rays | 2005 |
topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Camptothecin; Carrier Proteins; Cell Cycle; Cisplatin; DNA Damage; DNA Topoisomerases, Type I; DNA-Binding Proteins; Gene Expression Regulation; Genes, Tumor Suppressor; Humans; Mice; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Osteosarcoma; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Zinc Fingers | 2005 |
53BP1 is associated with replication protein A and is required for RPA2 hyperphosphorylation following DNA damage.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; DNA-Binding Proteins; Electrophoresis, Gel, Two-Dimensional; Flow Cytometry; Humans; Immunoblotting; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Mass Spectrometry; Osteosarcoma; Phosphoproteins; Phosphorylation; Replication Protein A; RNA, Small Interfering; Transfection; Tumor Suppressor p53-Binding Protein 1 | 2005 |
Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Clusterin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Osteosarcoma; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Time Factors; Up-Regulation | 2007 |
Osteosarcoma metastatic to the kidney and iatrogenic hemorrhage.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Bone Neoplasms; Calcinosis; Camptothecin; Child; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Hematuria; Hemorrhage; Humans; Iatrogenic Disease; Ilium; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Methotrexate; Osteosarcoma; Radiography; Tibia; Ultrasonography, Interventional | 2008 |
p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.
Topics: Apoptosis; Camptothecin; Carcinoma, Small Cell; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Enzyme Inhibitors; Humans; Mutation; Osteosarcoma; Tetracycline; Topoisomerase I Inhibitors; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
MDM2 oncogene as a target for cancer therapy: An antisense approach.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Division; Choriocarcinoma; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Nuclear Proteins; Oligonucleotides, Antisense; Osteosarcoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Survival Rate; Tumor Cells, Cultured | 1999 |
Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice.
Topics: Aerosols; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Electron; Neoplasm Transplantation; Neoplasms, Experimental; Osteosarcoma; Particle Size; Transplantation, Heterologous | 2000 |
9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Camptothecin; Drug Carriers; Female; Humans; Liposomes; Lung; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Osteosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice.
Topics: Aerosols; Animals; Antineoplastic Agents; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Microscopy, Electron; Osteosarcoma; Particle Size; Phosphatidylcholines; Xenograft Model Antitumor Assays | 2000 |
Vitamin D compounds exert anti-apoptotic effects in human osteosarcoma cells in vitro.
Topics: Apoptosis; Camptothecin; Humans; Osteosarcoma; Staurosporine; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vitamin D | 2001 |
Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Camptothecin; Drug Administration Schedule; Irinotecan; Male; Mice; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin | 2002 |
Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.
Topics: Aspartic Acid; Bone Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Enzyme Inhibitors; Gene Amplification; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mutation; Osteosarcoma; Phenotype; Phosphonoacetic Acid; Protein Structure, Tertiary; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Topics: Adenocarcinoma; Adult; Animals; Antineoplastic Agents; Camptothecin; Child; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Osteosarcoma; Remission Induction; Rhabdomyosarcoma; Time Factors; Topotecan; Tumor Cells, Cultured | 1992 |